Universitätsklinikum JENA

Universitätsklinikum JENA has been granted 13 US utility patents between 2016 and 2024, placing Universitätsklinikum JENA at rank #21,971 across all assignees tracked by PlainPatent. This portfolio spans 24 distinct Cooperative Patent Classification (CPC) subclasses, averaging 12.5 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a Foreign Corporation, Universitätsklinikum JENA is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 35.6/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 10 grants, compared with 3 in the 2015–2019 window, a +233% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Universitätsklinikum JENA's 12.5 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while a multi-domain presence across 24 subclasses balances depth with breadth. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Universitätsklinikum JENA against peers pursuing similar technology classes.